204 related articles for article (PubMed ID: 24743051)
41. Unusual acute and delayed skin reactions during and after whole-brain radiotherapy in combination with the BRAF inhibitor vemurafenib. Two case reports.
Schulze B; Meissner M; Wolter M; Rödel C; Weiss C
Strahlenther Onkol; 2014 Feb; 190(2):229-32. PubMed ID: 24362499
[TBL] [Abstract][Full Text] [Related]
42. Acute renal failure associated with the new BRAF inhibitor vemurafenib: a case series of 8 patients.
Launay-Vacher V; Zimner-Rapuch S; Poulalhon N; Fraisse T; Garrigue V; Gosselin M; Amet S; Janus N; Deray G
Cancer; 2014 Jul; 120(14):2158-63. PubMed ID: 24737576
[TBL] [Abstract][Full Text] [Related]
43. Vemurafenib (RG67204, PLX4032): a potent, selective BRAF kinase inhibitor.
Patrawala S; Puzanov I
Future Oncol; 2012 May; 8(5):509-23. PubMed ID: 22646766
[TBL] [Abstract][Full Text] [Related]
44. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics.
Ribas A; Zhang W; Chang I; Shirai K; Ernstoff MS; Daud A; Cowey CL; Daniels G; Seja E; O'Laco E; Glaspy JA; Chmielowski B; Hill T; Joe AK; Grippo JF
J Clin Pharmacol; 2014 Apr; 54(4):368-74. PubMed ID: 24374975
[TBL] [Abstract][Full Text] [Related]
45. Reproducible and sustained efficacy of targeted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Chester disease.
Haroche J; Cohen-Aubart F; Emile JF; Maksud P; Drier A; Tolédano D; Barete S; Charlotte F; Cluzel P; Donadieu J; Benameur N; Grenier PA; Besnard S; Ory JP; Lifermann F; Idbaih A; Granel B; Graffin B; Hervier B; Arnaud L; Amoura Z
J Clin Oncol; 2015 Feb; 33(5):411-8. PubMed ID: 25422482
[TBL] [Abstract][Full Text] [Related]
46. Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.
Dummer R; Goldinger SM; Turtschi CP; Eggmann NB; Michielin O; Mitchell L; Veronese L; Hilfiker PR; Felderer L; Rinderknecht JD
Eur J Cancer; 2014 Feb; 50(3):611-21. PubMed ID: 24295639
[TBL] [Abstract][Full Text] [Related]
47. BRAF inhibitor (vemurafenib) concurrent with radiation therapy for metastatic melanoma producing severe skin and oral cavity reactions.
Wallach JB; Rietschel P; Kalnicki S; Fox JL
Pract Radiat Oncol; 2014; 4(5):e213-e216. PubMed ID: 25194107
[No Abstract] [Full Text] [Related]
48. Vemurafenib skin phototoxicity is indirectly linked to ultraviolet A minimal erythema dose decrease.
Brugière C; Stefan A; Morice C; Cornet E; Moreau A; Allouche S; Verneuil L
Br J Dermatol; 2014 Dec; 171(6):1529-32. PubMed ID: 25066094
[TBL] [Abstract][Full Text] [Related]
49. The use of vemurafenib in Australian patients with unresectable or metastatic melanoma containing the V600 BRAF gene mutation.
Brown MP; Long GV
Asia Pac J Clin Oncol; 2014 Apr; 10 Suppl S3():1-15. PubMed ID: 24712861
[TBL] [Abstract][Full Text] [Related]
50. Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study.
Del Vecchio M; Ascierto PA; Mandalà M; Sileni VC; Maio M; Di Guardo L; Simeone E; Queirolo P
Future Oncol; 2015; 11(9):1355-62. PubMed ID: 25952781
[TBL] [Abstract][Full Text] [Related]
51. Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.
Regnier-Rosencher E; Lazareth H; Gressier L; Avril MF; Thervet E; Dupin N
Br J Dermatol; 2013 Oct; 169(4):934-8. PubMed ID: 23909652
[TBL] [Abstract][Full Text] [Related]
52. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma.
Larkin J; Ascierto PA; Dréno B; Atkinson V; Liszkay G; Maio M; Mandalà M; Demidov L; Stroyakovskiy D; Thomas L; de la Cruz-Merino L; Dutriaux C; Garbe C; Sovak MA; Chang I; Choong N; Hack SP; McArthur GA; Ribas A
N Engl J Med; 2014 Nov; 371(20):1867-76. PubMed ID: 25265494
[TBL] [Abstract][Full Text] [Related]
53. Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma.
Degen A; Völker B; Kapp A; Gutzmer R
Eur J Dermatol; 2013; 23(1):118. PubMed ID: 23419281
[No Abstract] [Full Text] [Related]
54. Vemurafenib in the French temporary authorization for use metastatic melanoma cohort: a single-centre trial.
Fennira F; Pagès C; Schneider P; Sidina I; Viguier M; Basset-Seguin N; Madjlessi-Ezra N; Madelaine I; Bagot M; Battistella M; Porcher R; Mourah S; Lebbé C
Melanoma Res; 2014 Feb; 24(1):75-82. PubMed ID: 24241686
[TBL] [Abstract][Full Text] [Related]
55. Dramatic response of vemurafenib-induced cutaneous lesions upon switch to dual BRAF/MEK inhibition in a metastatic melanoma patient.
Peters S; Bouchaab H; Zimmerman S; Bucher M; Gaide O; Letovanec I; Homicsko K; Michielin O
Melanoma Res; 2014 Oct; 24(5):496-500. PubMed ID: 25185693
[TBL] [Abstract][Full Text] [Related]
56. Vemurafenib beyond progression in a patient with metastatic melanoma: a case report.
Grimaldi AM; Simeone E; Palla M; Festino L; Caracò C; Mozzillo N; Petrillo A; Muto P; Ascierto PA
Anticancer Drugs; 2015 Apr; 26(4):464-8. PubMed ID: 25622086
[TBL] [Abstract][Full Text] [Related]
57. [Acantholytic dermatosis in patients treated by vemurafenib: 2 cases].
Sabatier-Vincent M; Charles J; Pinel N; Challende I; Claeys A; Leccia MT
Ann Dermatol Venereol; 2014 Nov; 141(11):689-93. PubMed ID: 25442474
[TBL] [Abstract][Full Text] [Related]
58. S100B and lactate dehydrogenase as response and progression markers during treatment with vemurafenib in patients with advanced melanoma.
Abusaif S; Jradi Z; Held L; Pflugfelder A; Weide B; Meier F; Garbe C; Eigentler TK
Melanoma Res; 2013 Oct; 23(5):396-401. PubMed ID: 23907232
[TBL] [Abstract][Full Text] [Related]
59. Radiation necrosis mimicking rapid intracranial progression of melanoma metastasis in two patients treated with vemurafenib.
Liebner DA; Walston SA; Cavaliere R; Powers CJ; Sauvageau E; Lehman NL; Wayne Slone H; Xu-Welliver M; Xia F; Kendra KL
Melanoma Res; 2014 Apr; 24(2):172-6. PubMed ID: 24407165
[TBL] [Abstract][Full Text] [Related]
60. Improved overall survival in melanoma with combined dabrafenib and trametinib.
Robert C; Karaszewska B; Schachter J; Rutkowski P; Mackiewicz A; Stroiakovski D; Lichinitser M; Dummer R; Grange F; Mortier L; Chiarion-Sileni V; Drucis K; Krajsova I; Hauschild A; Lorigan P; Wolter P; Long GV; Flaherty K; Nathan P; Ribas A; Martin AM; Sun P; Crist W; Legos J; Rubin SD; Little SM; Schadendorf D
N Engl J Med; 2015 Jan; 372(1):30-9. PubMed ID: 25399551
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
